Camurus (CAMX) Aandelenoverzicht
Camurus AB (publ), een biofarmaceutisch bedrijf, ontwikkelt en verkoopt geneesmiddelen voor ernstige en chronische ziekten in Europa, Afrika, het Midden-Oosten, Noord-Amerika en Azië. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 5/6 |
| Toekomstige groei | 6/6 |
| Prestaties in het verleden | 4/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
Geen risico's gedetecteerd voor CAMX uit onze risicocontroles.
CAMX Community Fair Values
Create NarrativeSee what 60 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Camurus AB (publ) Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | SEK 525.50 |
| 52 Week Hoogtepunt | SEK 754.50 |
| 52 Week Laag | SEK 430.80 |
| Bèta | 0.50 |
| 1 maand verandering | -7.56% |
| 3 maanden verandering | -1.31% |
| 1 Jaar Verandering | 3.75% |
| 3 jaar verandering | 82.34% |
| 5 jaar verandering | 158.23% |
| Verandering sinds IPO | 696.21% |
Recent nieuws en updates
Analyseartikel • May 20
The Strong Earnings Posted By Camurus (STO:CAMX) Are A Good Indication Of The Strength Of The Business
Investors were underwhelmed by the solid earnings posted by Camurus AB (publ) ( STO:CAMX ) recently. Our analysis says...Analyseartikel • May 15
Camurus AB (publ) Just Missed EPS By 29%: Here's What Analysts Think Will Happen Next
Camurus AB (publ) ( STO:CAMX ) missed earnings with its latest quarterly results, disappointing overly-optimistic...
Narratiefupdate • Apr 29
CAMX: 2026 Guidance And Earnings Outlook Will Drive Future Upside Potential
Analysts have trimmed their price target on Camurus to SEK770 from SEK814, reflecting updated views on fair value, discount rate and the balance between higher projected revenue growth and more moderate profit margins, with only a small adjustment to expected future P/E. What's in the News Camurus issued earnings guidance for 2026, setting expected revenues in a range of SEK 2.6b to SEK 2.9b (Key Developments).Recent updates
Analyseartikel • May 20
The Strong Earnings Posted By Camurus (STO:CAMX) Are A Good Indication Of The Strength Of The Business
Investors were underwhelmed by the solid earnings posted by Camurus AB (publ) ( STO:CAMX ) recently. Our analysis says...Analyseartikel • May 15
Camurus AB (publ) Just Missed EPS By 29%: Here's What Analysts Think Will Happen Next
Camurus AB (publ) ( STO:CAMX ) missed earnings with its latest quarterly results, disappointing overly-optimistic...Narratiefupdate • Apr 29
CAMX: 2026 Guidance And Earnings Outlook Will Drive Future Upside Potential
Analysts have trimmed their price target on Camurus to SEK770 from SEK814, reflecting updated views on fair value, discount rate and the balance between higher projected revenue growth and more moderate profit margins, with only a small adjustment to expected future P/E. What's in the News Camurus issued earnings guidance for 2026, setting expected revenues in a range of SEK 2.6b to SEK 2.9b (Key Developments).
Narratiefupdate • Apr 14
CAMX: 2026 Earnings Guidance Will Support Further Share Price Upside
Analysts have maintained their SEK 930 price target on Camurus, supported by updated forecasts that reflect slightly higher revenue growth, a marginally stronger profit margin, and a modestly lower future P/E assumption. What's in the News Camurus issued earnings guidance for 2026, with expected revenues in a range of SEK 2.6b to SEK 2.9b.
Narratiefupdate • Mar 31
CAMX: FDA Review Of Resubmitted NDA Will Drive Future Upside
Analysts have trimmed their 12 month price target for Camurus from SEK 660 to SEK 610, citing updated assumptions that include revised revenue growth, profit margin and future P/E expectations. What's in the News Camurus issued earnings guidance for 2026, with expected revenues of SEK 2.6b to SEK 2.9b and an operating result of SEK 0.9b to SEK 1.2b, framed against internal 2025 expectations (Key Developments).Narratiefupdate • Mar 17
CAMX: 2026 Guidance And US FDA Review Will Drive Future Upside
Analysts have kept their SEK 930 price target for Camurus unchanged, citing only minor adjustments in their assumptions for revenue growth, profit margin and future P/E as the main reasons for maintaining this level. What's in the News Camurus issued earnings guidance for 2026, with expected revenues of SEK 2.6b to SEK 2.9b and an operating result of SEK 0.9b to SEK 1.2b (Corporate guidance).Narratiefupdate • Mar 03
CAMX: Upcoming US And EU Launches Will Drive Future Upside Potential
Analysts have reset their price target on Camurus to SEK 930 from SEK 1,102, reflecting updated views on slightly higher forecast revenue growth, a modestly lower projected profit margin and a reduced future P/E multiple. What's in the News Camurus issued earnings guidance for 2026, expecting revenues of SEK 2.6b to SEK 2.9b and an operating result of SEK 0.9b to SEK 1.2b (Corporate guidance).Analyseartikel • Feb 18
These Analysts Just Made A Sizeable Downgrade To Their Camurus AB (publ) (STO:CAMX) EPS Forecasts
One thing we could say about the analysts on Camurus AB (publ) ( STO:CAMX ) - they aren't optimistic, having just made...Narratiefupdate • Feb 17
CAMX: FDA Review And New Partnership Will Drive Future Upside
Analysts have kept their SEK 660 price target for Camurus unchanged, with updated assumptions pointing to higher forecast revenue growth and a higher future P/E, alongside a lower projected profit margin. What's in the News Camurus issued earnings guidance for 2026, with expected revenues of SEK 2.6b to SEK 2.9b and an operating result of SEK 0.9b to SEK 1.2b, both framed relative to 2025 levels in the company communication (Corporate guidance).Narratiefupdate • Feb 03
CAMX: Obesity Data And Resubmitted NDA Will Drive Future Upside Potential
Analysts have lifted their price target on Camurus from SEK 793.71 to SEK 814.17, citing updated assumptions around revenue growth, margin potential, and a lower future P/E multiple as key drivers of the change. What's in the News The U.S. FDA accepted Camurus' resubmitted New Drug Application for Oclaiz (CAM2029) for acromegaly treatment and set a PDUFA target action date of 10 June 2026, following an earlier Complete Response Letter related to a third party manufacturing facility (Key Developments).Narratiefupdate • Jan 19
CAMX: Guidance Cut Will Be Offset By Pipeline Progress And New Partnership
Analysts have kept their price target for Camurus steady at SEK 660, citing updated assumptions around revenue growth, a profit margin of 72.87% and a future P/E of 12.70 as key inputs to their valuation work. What's in the News The U.S. FDA accepted Camurus' resubmitted New Drug Application for Oclaiz (CAM2029) for acromegaly, with a PDUFA target action date of 10 June 2026.Narratiefupdate • Jan 05
CAMX: Revised Outlook Will Balance Guidance Cut With Pipeline And Partnership Progress
Analysts have trimmed their Camurus fair value estimate from SEK 690.00 to SEK 660.00, citing updated assumptions for the discount rate, revenue growth, profit margin and future P/E. What's in the News Camurus revised its 2025 earnings guidance, now expecting total revenue of SEK 2.3b to SEK 2.6b, compared with the previous range of SEK 2.7b to SEK 3.0b, while keeping profit before tax guidance at SEK 0.9b to SEK 1.2b (Key Developments).Narratiefupdate • Dec 22
CAMX: Positive Obesity Data Will Drive Future Upside Potential
Narrative Update on Camurus Analysts have modestly raised their price target on Camurus to reflect a fair value of approximately SEK 794 per share, citing sustained strong revenue growth expectations and robust long term profit margins as key drivers of the upward revision. What's in the News Reported positive topline Phase 1b results for CAM2056, a monthly FluidCrystal semaglutide, showing dose dependent reductions in body weight, A1c, and fasting glucose that were comparable to or exceeded weekly semaglutide, with similar or better efficacy in a shorter treatment period (Key Developments).Narratiefupdate • Dec 08
CAMX: Positive Obesity Data And New EU Launch Will Drive Upside
Analysts have modestly trimmed their price target on Camurus, lowering it by approximately SEK 7 to reflect slightly softer long term revenue growth and margin assumptions, partly offset by a higher expected future earnings multiple. What's in the News Positive topline Phase 1b data for monthly GLP 1 candidate CAM2056 showed dose dependent reductions in body weight, A1c, and fasting glucose that were comparable to or exceeded weekly semaglutide, with a favorable extended release profile suitable for monthly dosing (Key Developments) In the Phase 1b trial, CAM2056 10 mg achieved a mean weight loss of 9.3 percent at Day 85 versus 5.2 percent for weekly semaglutide, with statistically significant treatment difference, and similar weight reduction after 3 months as weekly semaglutide after 5 months (Key Developments) Camurus lowered its 2025 revenue guidance to SEK 2.3 billion to SEK 2.6 billion from SEK 2.7 billion to SEK 3.0 billion, while maintaining profit before tax guidance at SEK 0.9 billion to SEK 1.2 billion (Key Developments) Camurus launched Oczyesa, an octreotide subcutaneous depot for maintenance treatment of adults with acromegaly previously stabilized on somatostatin analogs, in Germany as the first EU market (Key Developments) Valuation Changes Fair Value: Trimmed slightly from SEK 800.86 to SEK 793.71, reflecting a modest downward revision in intrinsic value estimates.Analyseartikel • Dec 08
Camurus AB (publ)'s (STO:CAMX) Intrinsic Value Is Potentially 69% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, Camurus fair value estimate is kr1,022 Camurus is estimated to...Narratiefupdate • Nov 24
CAMX: New European Launch And Regulatory Progress Will Drive Future Upside
Camurus's analyst price target has been slightly revised downward from SEK 801.17 to SEK 800.86. This change reflects updated assessments on growth and profitability expectations according to analysts.Analyseartikel • Nov 19
Analysts Have Just Cut Their Camurus AB (publ) (STO:CAMX) Revenue Estimates By 11%
Market forces rained on the parade of Camurus AB (publ) ( STO:CAMX ) shareholders today, when the analysts downgraded...Analyseartikel • Nov 09
Here's What Analysts Are Forecasting For Camurus AB (publ) (STO:CAMX) Following Its Earnings Miss
Camurus AB (publ) ( STO:CAMX ) just released its latest quarterly report and things are not looking great. It looks...Narratiefupdate • Nov 07
CAMX: European Market Launch And Regulatory Wins Will Drive Profitability Higher
Analysts have lowered their price target for Camurus from SEK 832.17 to SEK 801.17. They cite modestly higher discount rates and slower projected revenue growth, although the updated outlook includes improved profit margins.Analyseartikel • Oct 19
If EPS Growth Is Important To You, Camurus (STO:CAMX) Presents An Opportunity
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Narratiefupdate • Sep 04
Global Expansion And Regulatory Approvals Will Transform Healthcare Delivery
With key metrics such as future P/E (16.49x) and net profit margin (54.67%) remaining stable, Camurus’s fair value assessment is unchanged, with the consensus analyst price target holding steady at SEK832.17. What's in the News Camurus received UK MHRA marketing authorization for Oczyesa® (octreotide subcutaneous depot) for maintenance treatment of adult acromegaly patients, following comprehensive clinical studies including two Phase 3 trials.Analyseartikel • Jun 10
Should You Be Adding Camurus (STO:CAMX) To Your Watchlist Today?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analyseartikel • May 23
There May Be Underlying Issues With The Quality Of Camurus' (STO:CAMX) Earnings
Last week's profit announcement from Camurus AB (publ) ( STO:CAMX ) was underwhelming for investors, despite headline...Analyseartikel • May 08
There's No Escaping Camurus AB (publ)'s (STO:CAMX) Muted Revenues Despite A 27% Share Price Rise
Camurus AB (publ) ( STO:CAMX ) shares have had a really impressive month, gaining 27% after a shaky period beforehand...Analyseartikel • Mar 09
Camurus AB (publ)'s (STO:CAMX) Popularity With Investors Is Under Threat From Overpricing
There wouldn't be many who think Camurus AB (publ)'s ( STO:CAMX ) price-to-sales (or "P/S") ratio of 19.2x is worth a...
Nieuw narratief • Dec 30
Buvidal And Brixadi Expansion To Fuel Revenue Growth And Boost Profit Margins
Strong R&D pipeline and successful regulatory progress signal future revenue growth from new treatments entering various markets.Analyseartikel • Dec 07
Camurus AB (publ)'s (STO:CAMX) P/S Is On The Mark
You may think that with a price-to-sales (or "P/S") ratio of 19x Camurus AB (publ) ( STO:CAMX ) is a stock to...Analyseartikel • Nov 15
Investors Can Find Comfort In Camurus' (STO:CAMX) Earnings Quality
The market for Camurus AB (publ)'s ( STO:CAMX ) shares didn't move much after it posted weak earnings recently. We...Analyseartikel • Nov 10
Camurus AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Investors in Camurus AB (publ) ( STO:CAMX ) had a good week, as its shares rose 2.5% to close at kr615 following the...Analyseartikel • Aug 09
What Camurus AB (publ)'s (STO:CAMX) P/S Is Not Telling You
Camurus AB (publ)'s ( STO:CAMX ) price-to-sales (or "P/S") ratio of 24.3x might make it look like a sell right now...Analyseartikel • Jul 19
Earnings Miss: Camurus AB (publ) Missed EPS By 11% And Analysts Are Revising Their Forecasts
Last week, you might have seen that Camurus AB (publ) ( STO:CAMX ) released its second-quarter result to the market...Analyseartikel • Jul 12
We Ran A Stock Scan For Earnings Growth And Camurus (STO:CAMX) Passed With Ease
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analyseartikel • May 02
Camurus AB (publ)'s (STO:CAMX) CEO Will Probably Have Their Compensation Approved By Shareholders
Key Insights Camurus to hold its Annual General Meeting on 8th of May CEO Fredrik Tiberg's total compensation includes...Analyseartikel • Apr 19
Investors Appear Satisfied With Camurus AB (publ)'s (STO:CAMX) Prospects
There wouldn't be many who think Camurus AB (publ)'s ( STO:CAMX ) price-to-sales (or "P/S") ratio of 15.9x is worth a...Analyseartikel • Feb 22
Camurus' (STO:CAMX) Strong Earnings Are Of Good Quality
Camurus AB (publ)'s ( STO:CAMX ) earnings announcement last week was disappointing for investors, despite the decent...Rendement voor aandeelhouders
| CAMX | SE Pharmaceuticals | SE Markt | |
|---|---|---|---|
| 7D | 3.1% | 2.6% | 3.2% |
| 1Y | 3.8% | -7.9% | 14.4% |
Rendement versus industrie: CAMX overtrof de Swedish Pharmaceuticals industrie, die het afgelopen jaar een rendement -7.9 % opleverde.
Rendement versus markt: CAMX presteerde slechter dan Swedish Market, dat het afgelopen jaar een rendement van 14.4 % opleverde.
Prijsvolatiliteit
| CAMX volatility | |
|---|---|
| CAMX Average Weekly Movement | 5.8% |
| Pharmaceuticals Industry Average Movement | 7.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in SE Market | 13.3% |
| 10% least volatile stocks in SE Market | 3.7% |
Stabiele aandelenkoers: CAMX heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de Swedish markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van CAMX is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1991 | 274 | Fredrik Tiberg | www.camurus.com |
Camurus AB (publ), een biofarmaceutisch bedrijf, ontwikkelt en verkoopt geneesmiddelen voor ernstige en chronische ziekten in Europa, Afrika, het Midden-Oosten, Noord-Amerika en Azië. Het bedrijf biedt Buvidal, een buprenorfine-injectie voor de behandeling van opioïde afhankelijkheid en chronische pijn; en Brixadi voor de behandeling van opioïde gebruiksstoornissen. Het biedt ook CAM2038 voor de behandeling van chronische pijn; CAM2029, dat fase III klinische studies heeft voltooid voor de behandeling van acromegalie, en fase III klinische studies voor de behandeling van gastroenteropancreatische neuro-endocriene tumoren, evenals in fase II klinische studie voor de behandeling van polycysteuze leverziekten; en CAM2043 dat in fase I klinische studie is voor de behandeling van pulmonale arteriële hypertensie, evenals in fase II klinische studie voor de behandeling van het fenomeen van Raynaud.
Camurus AB (publ) Samenvatting
| CAMX fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | SEK 31.40b |
| Inkomsten(TTM) | SEK 682.13m |
| Inkomsten(TTM) | SEK 2.24b |
46.0x
Koers/Winstverhouding14.0x
P/S-verhoudingIs CAMX overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| CAMX resultatenrekening (TTM) | |
|---|---|
| Inkomsten | SEK 2.24b |
| Kosten van inkomsten | SEK 154.01m |
| Brutowinst | SEK 2.09b |
| Overige uitgaven | SEK 1.40b |
| Inkomsten | SEK 682.13m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
Jul 15, 2026
| Winst per aandeel (EPS) | 11.42 |
| Brutomarge | 93.13% |
| Nettowinstmarge | 30.45% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde CAMX op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/22 06:30 |
| Aandelenkoers aan het einde van de dag | 2026/05/22 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Camurus AB (publ) wordt gevolgd door 10 analisten. 8 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |
| Gonzalo Artiach Castanon | Danske Bank |
| Kristofer Liljeberg-Svensson | DNB Carnegie |